[Long-term syndrome in the treatment of parkinsonism with L-dopa and decarboxylase an inhibitor].
In 28% of patients treated for a long time with L-dopa, alone or combined with a decarboxilase inhibitor, the following "long-term syndrome" was observed: decrease in effectiveness, psychic disorders, intense abnormal movements, distonic attitudes, speech and gait disorders, orthostatic hypotension and/or general reprecussion. In 11% of the patients the "on-off" effect was studied (brisk alteranting Parkinsonic and improved states). Clinical observation during 14 hours a day was repeated with different dosages and different regimes of the drug; these modified the daily variations but did not eliminate the syndrome. The electromyographic studies also revealed the "on and off" phenomenon in different patients. When the "long-term syndrome" is severe, at times it is necessary to stop the drug; the secondary effects are thus decreased and, when the medication is given again, the therapeutic effectiveness is temporarily restored. When the drug is stopped the patients should be watched, since a "withdrawal syndrome" may appear.
D000328:Adult; D001545:Benserazide / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000009:adverse effects*; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*
D004338:Drug Combinations; D006834:Hydrazines; D007980:Levodopa; D001545:Benserazide
"Long-term syndrome" en el tratamiento del parkinsonismo con L-dopa y un inhibdor de la descarboxilasa